Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

A method of antibiotic treatment combines a pore-forming agent with histones, which stabilize the pores and inhibit transcription. This combination has a significant and complete effect on eliminating bacterial growth. A composition comprising a pore-forming agent and a histone, and optionally, a pharmaceutically acceptable carrier or excipient. The pore-forming agents can include LL-37, magainin, or polymyxin B. Examples of a histone include H2A and H3. A method for killing bacteria comprises contacting bacteria with a pore-forming agent and a histone, or with a composition of the invention. Also provided is a method for treating a bacterial infection in a subject, the method comprising administering a pore-forming agent and a histone to the subject, such as in the form of a composition of the invention. In some embodiments, the bacteria comprise Pseudomonas aeruginosa, Escherichia coli, and/or Staphylococcus aureus.

A method of antibiotic treatment combines a pore-forming agent with histones, which stabilize the pores and inhibit transcription. This combination has a significant and complete effect on eliminating bacterial growth. A composition comprising a pore-forming agent and a histone, and optionally, a pharmaceutically acceptable carrier or excipient. The pore-forming agents can include LL-37, magainin, or polymyxin B. Examples of a histone include H2A and H3. A method for killing bacteria comprises contacting bacteria with a pore-forming agent and a histone, or with a composition of the invention. Also provided is a method for treating a bacterial infection in a subject, the method comprising administering a pore-forming agent and a histone to the subject, such as in the form of a composition of the invention. In some embodiments, the bacteria comprise Pseudomonas aeruginosa, Escherichia coli, and/or Staphylococcus aureus.

The present invention relates generally to a method of reducing unwanted airway tissue mucus secretion in a mammal and to agents useful for same. More particularly, the present invention relates to a method of reducing airway tissue mucus hypersecretion in a mammal by downregulating the functional level of activin or upregulating the functional level of follistatin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by airway tissue mucus dysfunction, such as overproduction of mucus or decreased mucus clearance, and where a reduction in mucus secretion levels would thereby alleviate the condition.

Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.

Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.

Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.